## 3 Results
### Analysis Part
#### 3.2.2 Temporal In Vitro Stability Tests of All DFMACs in Simulated Body Fluids  
In oral drug delivery systems, a drug can pass through six different types of body fluids such as simulated gastric fluid, simulated intestinal fluid and simulated colonic fluid in a fasted-state/fed-state. The composition of those body fluids affects the possible in vivo behavior of a drug. Sodium chloride is present in fasted-state/fed-state simulated gastric fluid and fasted-state/fed-state simulated intestinal fluid. PBS (phosphate buffer saline) is used to mimic colonic fluid [41]. Additionally, 5% dextrose solution can stay in gastric fluid due to food intake in fed-state [42]. To understand the behavior of the orally administered drug in the gastrointestinal tract, different environmental solutions and various pH values \begin{table}
\begin{tabular}{c c c c c c c c c} \hline \hline
**pH** & **AMP** & **CEF** & \begin{tabular}{c} **PMVEMA-** \\ **AMP** \\ \end{tabular} & \begin{tabular}{c} **PIBMA-** \\ **AMP** \\ \end{tabular} & \begin{tabular}{c} **PEMA-** \\ **AMP** \\ \end{tabular} & \begin{tabular}{c} **PMA-** \\ **CEP** \\ \end{tabular} & \
\begin{tabular}{c} **PMVEMA-** \\ **CEF** \\ \end{tabular} &
\begin{tabular}{c} **PIBMA-** \\ **CEF** \\ \end{tabular} \\ \hline
2 & \(-2.1\) & \(-4.8\) & \(-13.7\) & \(-10.9\) & \(-9.9\) & \(-14.1\) & \(-10.2\) & \(-11.9\) \\
3 & \(-2.4\) & \(-8.5\) & \(-15.9\) & \(-11.9\) & \(-10.1\) & \(-14.6\) & \(-16.4\) & \(-13.4\) \\
4 & \(-4.5\) & \(-18.9\) & \(-20.0\) & \(-17.8\) & \(-16.5\) & \(-14.9\) & \(-17.9\) & \(-14.9\) \\
5 & \(-9.8\) & \(-19.4\) & \(-32.1\) & \(-25.2\) & \(-17.3\) & \(-24.3\) & \(-20.5\) & \(-17.2\) \\
6 & \(-5.1\) & \(-19.7\) & \(-36.8\) & \(-25.2\) & \(-20.0\) & \(-22.7\) & \(-24.2\) & \(-20.9\) \\
7 & \(-10.5\) & \(-16.2\) & \(-38.5\) & \(-22.9\) & \(-21.2\) & \(-22.4\) & \(-20.5\) & \(-22.4\) \\
8 & \(-11.9\) & \(-16.7\) & \(-29.0\) & \(-22.8\) & \(-22.2\) & \(-22.3\) & \(-17.9\) & \(-21.9\) \\
9 & \(-12.6\) & \(-21.2\) & \(-27.8\) & \(-15.6\) & \(-21.5\) & \(-21.2\) & \(-17.7\) & \(-19.7\) \\
10 & \(-12.6\) & \(-20.1\) & \(-27.7\) & \(-23.8\) & \(-21.4\) & \(-19.4\) & \(-17.6\) & \(-18.2\) \\
11 & \(-14.4\) & \(-21.9\) & \(-25.8\) & \(-21.4\) & \(-19.4\) & \(-19.2\) & \(-17.4\) & \(-16.2\) \\
12 & \(-24.2\) & \(-18.2\) & \(-23.8\) & \(-16.7\) & \(-19.6\) & \(-17.7\) & \(-16.9\) & \(-12.3\) \\
13 & \(-15.5\) & \(-16.0\) & \(-20.6\) & \(-14.9\) & \(-18.4\) & \(-14.8\) & \(-12.9\) & \(-10.8\) \\ \hline Mean, SD & \(-10.5\pm 6.3\) & \(-16.8\pm 5.1\) & \(-26.0\pm 7.7\) & \(-19.1\pm 5.1\) & \(-18.1\pm 4.2\) & \(-19.0\pm 3.7\) & \(-17.5\pm 3.6\) & \(-16.7\pm 4.0\) \\ \hline U & 1.8 & 1.5 & 2.2 & 1.5 & 1.2 & 1.1 & 1.0 & 1.2 \\ \hline \hline \end{tabular}
\end{table} 
Table 4: The zeta potential values (mV) of AMP, CEF and DFMACs at different pH values. \begin{table}
\begin{tabular}{c c c c c c c c c} \hline \hline
**pH** & **AMP** & **CEF** & \begin{tabular}{c} **PMVEMA-** \\ **AMP** \\ \end{tabular}  & \begin{tabular}{c} **PIBMA-** \\ **AMP** \\ \end{tabular}  & \begin{tabular}{c} **PEMA-** \\ **AMP** \\ \end{tabular}  & \begin{tabular}{c} **PMVEMA-** \\ **AMP** \\ \end{tabular}  & \begin{tabular}{c} **PIBMA-** \\ **CEP** \\ \end{tabular}  & \ \begin{tabular}{c} **PEMA-** \\ **CEF** \\ \end{tabular}  & \begin{tabular}{c} **PMVEMA-** \\ **CEF** \\ \end{tabular}  \\ \hline
2 & \(870\) & \(560\) & \(990\) & \(672\) & \(960\) & \(756\) & \(767\) & \(851\) \\
3 & \(850\) & \(485\) & \(890\) & \(396\) & \(765\) & \(494\) & \(708\) & \(764\) \\
4 & \(750\) & \(490\) & \(300\) & \(207\) & \(679\) & \(85\) & \(657\) & \(530\) \\
5  
should be considered. Temporal in vitro stability tests should be conducted to understand the changing behavior of novel DFMACs over a three-week period. The polydispersity index values of AMP, CEF and all DFMACs in 5% dextrose solution are given in Table 5.  
According to Table 5, all particles of drugs and DFMACs were monodispersed. The homogeneity of particles of DFMACs was not much affected by time.